Semaglutide for Weight Management

Educational content only. The following article is based on published scientific research and is provided for informational purposes. It does not constitute medical advice, diagnosis, or a treatment recommendation. Individual responses to any therapy vary. All peptide protocols at Irvine Health are available only after a licensed physician video consultation and a written prescription.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes that has since been studied extensively for weight management in adults with obesity. It works by mimicking the body's own GLP-1 hormone — slowing gastric emptying, reducing appetite signaling in the hypothalamus, and promoting satiety. Its chemical structure is 94% identical to native human GLP-1, modified with a fatty-acid side chain that extends its half-life to approximately seven days, allowing once-weekly subcutaneous administration.

What the Research Shows

STEP 1 Trial — Wilding et al., NEJM (2021)

In 1,961 adults with overweight or obesity (without type 2 diabetes), once-weekly subcutaneous semaglutide 2.4 mg produced a mean body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo plus lifestyle intervention. Eighty-six percent of participants on semaglutide achieved ≥5% weight loss.

STEP 4 Trial — Rubino et al., JAMA (2021)

Participants who had achieved stable weight loss on semaglutide after 20 weeks were randomized to continue semaglutide or switch to placebo. Those who continued semaglutide maintained their loss; those who switched regained approximately two-thirds of their lost weight by week 68, highlighting the need for ongoing management strategies.

SELECT Cardiovascular Outcomes Trial — Lincoff et al., NEJM (2023)

In 17,604 adults with pre-existing cardiovascular disease and overweight or obesity (without diabetes), semaglutide 2.4 mg reduced the composite risk of major adverse cardiovascular events by 20% versus placebo over a mean follow-up of 34 months — the first weight-management therapy to demonstrate this cardiovascular benefit.

Mechanism of Action

GLP-1 receptors are widely distributed throughout the body — in the pancreas, gut, heart, kidney, and central nervous system. Semaglutide's central nervous system effects on the hypothalamus and brainstem appear particularly important in reducing caloric intake by modulating reward pathways and hunger signals. The peripheral effect on gastric emptying contributes to prolonged postprandial satiety.

Common Areas of Clinical Interest

Weight management in adults with a BMI ≥30, or ≥27 with a weight-related comorbidity
Glycemic management in type 2 diabetes (lower dose formulations)
Cardiovascular risk reduction in qualifying patients
Non-alcoholic steatohepatitis (NASH) — active research area

Safety Profile

The most frequently reported adverse effects in clinical trials were gastrointestinal: nausea (44% vs 16% placebo in STEP 1), vomiting, diarrhea, and constipation — most commonly occurring during the dose-escalation period. Serious adverse events were low but included rare cases of pancreatitis. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 are typically excluded. A thorough medical history and ongoing monitoring are essential components of any protocol.

Compounded semaglutide has been the subject of FDA safety communications regarding purity and dosing accuracy, underscoring the importance of physician oversight and pharmacy sourcing from licensed 503A compounding pharmacies.

References

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity. JAMA. 2021;325(14):1414-1425.
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.
Ryan DH, et al. STEP 8 Trial: Semaglutide versus liraglutide for weight management. JAMA. 2023;329(10):841-852.
FDA. Highlights of Prescribing Information: Wegovy (semaglutide) injection 2.4 mg. 2021.